Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Ani Pharmaceuticals (ANIP) stock was recently in focus after the company reported statistically significant topline results from its Phase 4 SYNCHRONICITY trial of a fluocinolone acetonide intravitreal implant for chronic non infectious posterior segment uveitis.
See our latest analysis for ANI Pharmaceuticals.
Despite the positive SYNCHRONICITY data, ANI Pharmaceuticals’ recent share price return has been soft, with the stock down 6.13% over the past month and 1.96% over the past week. However, its 1 year total shareholder return of 15.07% and 5 year total shareholder return of 128.85% point to a much stronger longer term outcome.
If this kind of healthcare news has your attention, it can be useful to see what else is moving in adjacent areas of medicine, starting with 39 healthcare AI stocks
ANI Pharmaceuticals now trades well below both analyst targets and one estimate of intrinsic value after a soft recent share price move, so is the market rightly cautious about the story here, or overly discounting it?
Most Popular Narrative: 31.1% Undervalued
ANI Pharmaceuticals closed at $77.65, while the most followed narrative pegs fair value at $112.71, creating a sizable gap that hinges on the company’s long term earnings power.
The analysts are assuming ANI Pharmaceuticals’s revenue will grow by 14.1% annually over the next 3 years. Analysts assume that profit margins will increase from 9.1% today to 20.3% in 3 years time.
Want to see what sits behind that sharp profit ramp and higher margin profile for ANI Pharmaceuticals? The narrative leans on rising earnings, a richer mix and a leaner profit multiple tied to those future numbers.
Result: Fair Value of $112.71 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, ANI Pharmaceuticals still faces payer pushback risks around Cortrophin Gel, as well as potential margin pressure once exclusivity on key generics winds down.
Find out about the key risks to this ANI Pharmaceuticals narrative.
Next Steps
Seeing both bullish and cautious signals around ANI Pharmaceuticals, it makes sense to review the details yourself and decide where you stand, especially with 4 key rewards and 3 important warning signs.
Looking for more investment ideas beyond ANI Pharmaceuticals?
If ANI Pharmaceuticals has sharpened your interest, do not stop here. Use the Simply Wall St Screener to spot other stocks that could suit your approach.